Agenus

Positives: pruning to focus on BOT+BAL, monetization of noncore assets (sale of biologics manufacturing operations to Zydus with a collaboration that secures long‑term U.S. capacity), and use of early‑access frameworks to seed markets.

Negatives: heavy reliance on equity raises and warrants, recurring going‑concern flags, and large non‑cash royalty revenue that flatters optics but not liquidity. The pivot away from metastatic CRC Phase 3 to a neoadjuvant program is strategically defensible but lengthens time to cash generation.

Net‑net, capital allocation reflects survival and optionality, not compounding.